美国 · SEC FORM 4
Forte Biosciences, Inc.
FBRX · — · CIK 0001419041 · Healthcare
内部人信号
0 qualifying P purchase groups
当前 180 天评分窗口
8 同一窗口内观察到的 Form 4 交易行
0 sales · 8 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号？
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
—
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后，这些模块才会启用。
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2025-12-30 · Riley Antony A.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
FINRA 报告中没有该股票代码的空头余额。
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2025-12-30 | Riley Antony A | 买入 (P) | Common Stock | 9,680 | USD 26.33 | USD 254,874 | SEC 申报 ↗ |
| 2024-11-21 | Riley Antony A | 买入 (P) | Common Stock | 22,514 | USD 5.55 | USD 124,953 | SEC 申报 ↗ |
| 2023-12-18 | Wagner Paul A. | 买入 (P) | Common Stock | 10,000 | USD 0.75 | USD 7,500 | SEC 申报 ↗ |
| 2023-12-14 | Wagner Paul A. | 买入 (P) | Common Stock | 10,000 | USD 0.72 | USD 7,200 | SEC 申报 ↗ |
| 2023-12-13 | Wagner Paul A. | 买入 (P) | Common Stock | 10,520 | USD 0.70 | USD 7,364 | SEC 申报 ↗ |
| 2023-12-12 | Wagner Paul A. | 买入 (P) | Common Stock | 4,776 | USD 0.65 | USD 3,104 | SEC 申报 ↗ |
| 2023-12-11 | Wagner Paul A. | 买入 (P) | Common Stock | 25,000 | USD 0.65 | USD 16,250 | SEC 申报 ↗ |
| 2023-12-08 | Wagner Paul A. | 买入 (P) | Common Stock | 15,000 | USD 0.62 | USD 9,300 | SEC 申报 ↗ |
| 2023-12-07 | Wagner Paul A. | 买入 (P) | Common Stock | 36,203 | USD 0.58 | USD 20,998 | SEC 申报 ↗ |
| 2023-11-22 | Wagner Paul A. | 买入 (P) | Common Stock | 400 | USD 0.43 | USD 172 | SEC 申报 ↗ |
| 2023-11-20 | Wagner Paul A. | 买入 (P) | Common Stock | 6,966 | USD 0.44 | USD 3,048 | SEC 申报 ↗ |
| 2022-12-16 | Wagner Paul A. | 买入 (P) | Common Stock | 44,024 | USD 1.07 | USD 47,106 | SEC 申报 ↗ |
| 2022-12-15 | Wagner Paul A. | 买入 (P) | Common Stock | 55,976 | USD 1.03 | USD 57,655 | SEC 申报 ↗ |
| 2020-06-29 | Riley Antony A | 买入 (P) | Common Stock | 2,000 | USD 14.11 | USD 28,220 | SEC 申报 ↗ |
| 2020-06-26 | Riley Antony A | 买入 (P) | Common Stock | 4,700 | USD 14.52 | USD 68,244 | SEC 申报 ↗ |
Form 4 申报证据
17 transaction lines in the latest 365-day window; 100 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-08-27 | Wagner Paul A. | U (U) | Common Stock | 85,482 | USD — | USD — | SEC 申报 ↗ |
| 2026-08-27 | Riley Antony A | U (U) | Common Stock | 42,600 | USD — | USD — | SEC 申报 ↗ |
| 2026-08-27 | Kornfeld Steven | U (U) | Common Stock | 3,960 | USD — | USD — | SEC 申报 ↗ |
展开近期 Form 4 证据 (17 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-08-27 | Wagner Paul A. | U (U) | Common Stock | 85,482 | USD — | USD — | SEC 申报 ↗ |
| 2026-08-27 | Riley Antony A | U (U) | Common Stock | 42,600 | USD — | USD — | SEC 申报 ↗ |
| 2026-08-27 | Kornfeld Steven | U (U) | Common Stock | 3,960 | USD — | USD — | SEC 申报 ↗ |
| 2026-08-27 | GRYSKA DAVID W | U (U) | Common Stock | 5,940 | USD — | USD — | SEC 申报 ↗ |
| 2026-07-01 | Wagner Paul A. | 期权行权／转换 (M) | Common Stock | 1,250 | USD — | USD — | SEC 申报 ↗ |
| 2026-07-01 | Wagner Paul A. | 代扣税 (F) | Common Stock | 98 | USD 21.32 | USD 2,089 | SEC 申报 ↗ |
| 2026-07-01 | Riley Antony A | 期权行权／转换 (M) | Common Stock | 375 | USD — | USD — | SEC 申报 ↗ |
| 2026-07-01 | Riley Antony A | 代扣税 (F) | Common Stock | 134 | USD 21.32 | USD 2,857 | SEC 申报 ↗ |
| 2026-04-01 | Wagner Paul A. | 期权行权／转换 (M) | Common Stock | 1,250 | USD — | USD — | SEC 申报 ↗ |
| 2026-04-01 | Wagner Paul A. | 代扣税 (F) | Common Stock | 98 | USD 24.86 | USD 2,436 | SEC 申报 ↗ |
| 2026-04-01 | Riley Antony A | 期权行权／转换 (M) | Common Stock | 375 | USD — | USD — | SEC 申报 ↗ |
| 2026-04-01 | Riley Antony A | 代扣税 (F) | Common Stock | 134 | USD 24.86 | USD 3,331 | SEC 申报 ↗ |
| 2026-01-01 | Wagner Paul A. | 期权行权／转换 (M) | Common Stock | 1,250 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-01-01 | Wagner Paul A. | 代扣税 (F) | Common Stock | 164 | USD 27.27 | USD 4,472 | SEC 申报 ↗ |
| 2026-01-01 | Riley Antony A | 期权行权／转换 (M) | Common Stock | 375 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-01-01 | Riley Antony A | 代扣税 (F) | Common Stock | 154 | USD 27.27 | USD 4,200 | SEC 申报 ↗ |
| 2025-12-30 | Riley Antony A | 买入 (P) | Common Stock | 9,680 | USD 26.33 | USD 254,874 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | FBRX |
| CIK | 0001419041 |
| 行业 | Healthcare |
| 细分行业 | — Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | — |
数据覆盖
| 本地 Form 4 历史 | 100 transaction lines from 2020-02-26 to 2026-08-27 20 P purchase lines · 3 S sale lines · 77 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.